mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma

Abstract Sirolimus is a regularly applied immunosuppressant for patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Sirolimus not only significantly inhibits HCC recurrence but also protects renal function. However, the improvement effect of sirolimus on nontumour-rela...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Molecular Biomedicine
المؤلفون الرئيسيون: Lincheng Zhang, Peng Liu, Li Zhuang, Sunbin Ling, Qifan Zhan, Wei Zhou, Renyi Su, Lu Yin, Qingyang Que, Jiachen Hong, Jiaqi Bao, Chuxiao Shao, Jinzhen Cai, Shusen Zheng, Xiao Xu
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Springer 2024-03-01
الموضوعات:
Sirolimus
Liver transplantation
Hepatocellular carcinoma
Nontumour-related death
الوصول للمادة أونلاين:https://doi.org/10.1186/s43556-024-00170-6

الانترنت

https://doi.org/10.1186/s43556-024-00170-6

مواد مشابهة